Jeffrey Letzer

Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

Nathan Fowler, Brad S. Kahl, Peter P. Lee et al. · Journal of Clinical Oncology · 2011 · 108 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin’s lymphoma

A. Tulpule, Mark U. Rarick, Jonathan E. Kolitz et al. · Annals of Oncology · 2001 · 19 citations

Medicine, Oncology, Pharmacology +12

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Nathan Fowler, Brad S. Kahl, Peter J. Rosen et al. · Blood · 2009 · 18 citations

Medicine, Oncology, Pharmacotherapy +14

Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study

J. Matouš, Jeffrey Letzer, Peter J. Rosen et al. · Journal of Clinical Oncology · 2009 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +15